|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61K 31/4375 | (2006.01) | ||
| A61P 25/00 | (2006.01) |
| (11) | Number of the document | 3368534 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16794479.2 |
| Date of filing the European patent application | 2016-10-28 | |
| (97) | Date of publication of the European application | 2018-09-05 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-27 |
| (46) | Date of publication of the claims translation | 2021-04-12 |
| (86) | Number | PCT/US2016/059306 |
| Date | 2016-10-28 |
| (87) | Number | WO 2017/075340 |
| Date | 2017-05-04 |
| (30) | Number | Date | Country code |
| 201562249074 P | 2015-10-30 | US |
| (72) |
MCGEE, Kevin, US
ZOOK, Scott, US
CARR, Andrew, GB
BONNAUD, Thierry, GB
|
| (73) |
NEUROCRINE BIOSCIENCES, INC.,
12780 El Camino Real, San Diego, CA 92130,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Valbenazino ditozilatas ir jo polimorfai |
| VALBENAZINE DITOSYLATE AND POLYMORPHS THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-10-01 | 10 | 231.00 EUR |
| 2026-10-28 |